Objectives: Streptokinase, a protein produced by group C streptococci, is prescribed as a thrombosis treatment for the patients who suffer from acute myocardial infarction. Antibodies that are produced to neutralize streptokinase are challenges in treatment of MI patient particularly those who experience the attack for the second time. The purpose of this study was to introduce a simple enzyme ...

Neutralization of streptokinase by an unsuspected high titer of antistreptokinase antibody prevented activation of the fibrinolytic system and induction of a lytic state in a 62 year old man with an acute inferior myocardial infarction. There was no decrease in serum fibrinogen, minimal decrease in serum plasminogen and only a small increase in serum fibrin degradation products after intravenou...

The Indigenous population of the Northern Territory of Australia (NT) suffers from a very high burden of Streptococcus pyogenes disease, including cardiac and renal sequelae. The aim of this study was to determine if S. pyogenes isolated from this population represent NT endemic strains, or conversely reflect strains with global distribution. emm sequence typing data were used to select 460 S. ...

Edicine is a therapeutic agent in the management of thromboembolic blockade. Streptokinase presently utilized clinical mase and an extracellular protein secreted by certain strains beta-hemolytic streptococci. It activates plasminogen to produce plasmin, enzyme that breaks down fibrin clots through specific lysine binding sites.

Streptococcus pyogenes, is an important human pathogen classified within the pyogenic group of streptococci, exclusively adapted to the human host. Our goal was to employ a comparative evolutionary approach to better understand the genomic events concomitant with S. pyogenes human adaptation. As part of ascertaining these events, we sequenced the genome of one of the potential sister species, t...

The purpose of this study was to determine whether streptokinase (1) exacerbates intramyocardial hemorrhage during coronary reperfusion, (2) has any intrinsic effect on myocardial infarct size other than its ability to lyse proximal thrombi in coronary arteries, and (3) can abolish the no-reflow phenomenon. Anesthetized open-chest dogs underwent coronary occlusion for 3 hr followed by 3 hr of r...

It has been shown that the activation of bovine plasminogen by streptokinase plus a trace amount of human globulin involves a two-stage activation process (1, 2). Ablondi and Hagan (3) proposed that the proactivator of bovine plasminogen was identical with human plasminogen, which became activator by forming complexes with streptokinase. Kline and Fishman (4) using a lysine methyl ester assay d...

Tissue type plasminogen activator (t-PA) is an effective thrombolytic agent in experimental animals. The duration of the thrombolytic effect of infused t-PA is unknown. We compared the duration of the thrombolytic effect of t-PA with streptokinase by measuring the lysis of 125I-fibrin-labeled thrombi in rabbit jugular veins at different times after a bolus injection of the fibrinolytic agents. ...